|
|
|
|
|
|
|
25.09.26 - 19:01
|
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer (GlobeNewswire EN)
|
|
|
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical data from studies evaluating SLS009 (tambiciclib), its highly selective cyclin-dependent kinases 9 (CDK9) inhibitor, in patient-derived organoid models of pancreatic ductal adenocarcinoma (PDAC). The data are being presented at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, being held September 25–28, 2026, in San Diego. The timing of this announcement reflects AACR's embargo policy, under which the data presented at the conference were restricted from publication until 1:00 p.m. ET today....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.03.26 - 13:06
|
SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths (24/7 Wall St.)
|
|
|
A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group (NASDAQ:SLS) is at a genuinely unusual inflection point. Its shares have climbed 346% over the past year, yet the stock pulled back 13.4% in the past week to $5.04, with Q4 earnings due March 19. The reason Reddit is buzzing: ... SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths
The post SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
14.01.26 - 14:33
|
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe (GlobeNewswire EN)
|
|
|
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into an agreement with IMPACT-AML, a European collaborative initiative dedicated to advancing innovative treatments for patients with acute myeloid leukemia (AML). Under the agreement, the IMPACT-AML network will conduct a clinical study evaluating SLS009, a highly selective CDK9 inhibitor, enabling access to multiple European clinical sites and patients....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
